Molecular testing, frequency of molecular alterations and targeted 1st-line treatment of patients with non-small cell lung carcinoma in Germany: First results from the prospective German Registry CRISP (AIO-TRK-0315).

Griesinger, Frank; Eberhardt, Wilfried Ernst Erich; Nusch, Arnd; Reiser, Marcel; Zahn, Mark‐Oliver; Marschner, Norbert; Jänicke, Martina; Fleitz, A.; Spring, Lisa; Sahlmann, Joerg; Karatas, Aysun; Hipper, A.; Weichert, Wilko; Rittmeyer, Achim; Metzenmacher, Martin; Waller, Cornelius F.; Sebastian, Martin; Thomas, Michael

doi:10.1200/jco.2018.36.15_suppl.e21236

Cited by 7 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings are in line with data from national clinical research platform CRISP (NCT02622581) prospectively recruiting NSCLC patients from 144 cancer centers. In this study, an interim analysis revealed that 29% of patients were treated with osimertinib in second-line, however, as much as 42% of patients did not continue with second-line therapy after the initial treatment [30]. Additional RWE datasets from other countries reveal a similar picture.…”

Section: High Attrition Rates Limit Access Of Nsclc Patients To Second-line Therapymentioning

confidence: 60%

“…Additional RWE datasets from other countries reveal a similar picture. In Japanese prospective observational study REMEDY (UMIN000024928), only 10% of patients do not Real-world evidence on the portion of patients receiving systemic second-line therapy with osimertinib after progression on first-line EGFR-tyrosine kinase inhibitor in Germany [26,29,30].…”

Section: High Attrition Rates Limit Access Of Nsclc Patients To Second-line Therapymentioning

confidence: 99%

See 1 more Smart Citation

Optimizing Therapy Sequence to Prevent Patient Attrition in EGFR Mutation-Positive Advanced or Metastatic NSCLC

et al. 2020

Self Cite

View full text Add to dashboard Cite

Clinical trial and real-world data in non-small-cell lung cancer indicate that 10–60% of patients that progressed on first- or second-generation EGFR-targeting tyrosine kinase inhibitors (TKI) do not receive systemic second-line therapy. In our article, we discuss efficacy, safety and treatment duration with different EGFR-TKIs and stress the need for delivery of the most efficacious therapy in the first-line. We also provide our perspective on analysis of circulating tumor DNA and the role of EGFR-TKI in combined therapies. Finally, we review new therapeutic options to overcome resistance to EGFR-TKI. We believe that overall treatment duration and access to different medications in subsequent lines of therapy should be considered when planning the optimal treatment strategy.

show abstract

Section: High Attrition Rates Limit Access Of Nsclc Patients To Second-line Therapymentioning

confidence: 60%

Section: High Attrition Rates Limit Access Of Nsclc Patients To Second-line Therapymentioning

confidence: 99%

Optimizing Therapy Sequence to Prevent Patient Attrition in EGFR Mutation-Positive Advanced or Metastatic NSCLC

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…PFS, ORR (28 vs. 48%) and QoL were also significantly improved with Pembrolizmab single agent. Test rates have improved in Germany from 20 to 75%, however not every patient that is tested will receive Pembrolizumab in 1st line [6]. On the basis of KN 189 and KN 407 studies, patients with a high PD-L1 expression are also amenable for a combined ICI and chemotherapy treatment.…”

Section: Pd-l1 Expression > 50% Without Driver Mutationmentioning

confidence: 99%

“…These dramatic changes in outcome can only be achieved if patients are tested for the relevant "biomarkers" , i.e. genetic alterations EGFR, ALK, ROS, BRAF (mandatory) and PD-L1 before the start of treatment to allow an optimal 1st line treatment stratification [3][4][5][6]. This article describes the treatment strategies in patients with NSCLC without driver mutations.…”

Section: Introductionmentioning

confidence: 99%

Immune-Therapy Standards Of Care

Griesinger¹

2019

IJOPRS

Self Cite

View full text Add to dashboard Cite

“…Erst kürzlich konnten wir Unterschiede im Überleben unter TKIs bei kleineren Subgruppen finden (ALK/p53 mutiert vs. ALK/p53-Wildtyp), sodass innerhalb unseres Verbundes für solche kleineren Subgruppen verbesserte kombinatorische Subgruppen getestet werden können [5,6]. Außerdem schließt das nNGM eine wichtige Versorgungslücke: Realworld-Daten aus dem CRISP ("Clinical Research Platform Into Molecular Testing, Treatment and Outcome of Non-Small Cell Lung Carcinoma Patients") zeigen, dass mehr als 10 Jahre nach Einführung von EGFR-TKI-Therapie noch immer mehr als jeder vierte Lungenkrebspatient nicht vor auf EGFR-Mutationen vor der Erstlinientherapie getestet wird [7].…”

unclassified